Android app on Google Play

CRT Capital Cuts Valeant Pharma (VRX) to Fairly Valued

May 3, 2012 2:08 PM EDT Send to a Friend
Get Alerts VRX Hot Sheet
Price: $133.23 --0%

Rating Summary:
    13 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 9 | New: 6
Trade VRX Now!
Join SI Premium – FREE
CRT Capital's Timothy Chiang downgraded shares of Valeant Pharmaceuticals (NYSE: VRX) from Buy to Fairly Valued Thursday afternoon.

The downgrade follows Q1 results from the company and news it will acquire AcneFree and certain assets from University Medical. Shares are down more than 9 percent at last check.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.




You May Also Be Interested In


Related Categories

Downgrades

Related Entities

Earnings

Add Your Comment